



DIABETES MELLITUS

Diabetes Trials: the Julius Clinical Solution

Julius Clinical manages global clinical drug trials that will have a major impact on medicine and make a real difference to people's lives around the world.

Our unique combination of scientific leadership and operational excellence ensures that the trial data is of the highest quality. Our internationally recognised academic leaders are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility combined with operational excellence means that we are uniquely equipped to assist in providing answers for today's clinical drug development challenges.

Diabetes Mellitus is a global problem. It is a costly and serious disease which is becoming increasingly common, especially in developing countries and disadvantaged minorities. The World Health Organisation (WHO) estimates that approximately 150 million people have diabetes mellitus worldwide and this number may well double by 2025. While it is not curable, pharmaceutical companies are constantly looking for better and more effective treatments. This has resulted in a plethora of trials by many companies, trials which do not always result in new treatments. The most important complications of diabetes are cardiovascular and renal conditions. Because of these, there remains a large unmet need in diabetes patients. In addition, trials are normally conducted over a number of years, which increases the challenges of patient recruitment and retention.



DIABETES MELLITUS

The Challenges:

- Large competition (# drugs, # companies) affecting trial execution
- Lack of 'really novel' drugs with benefits beyond only glucose
- Large study size and long study duration
- Difficult to conduct Real World Evidence studies

Our Solution:

- High quality sites through a multi-country primary care research network
- Global scientific networks ensure high patient recruitment and retention
- Deep in-house understanding and expertise in Diabetes
- Peer-to-peer leadership model facilitates recruitment

TRACK RECORD (a selection) | INFECTIOUS DISEASES

STUDY	PERIOD	PATIENTS JC	THERAPEUTIC AREA
ADVANCE	2001 - 2008	3.231	Type 2 Diabetes
ALTITUDE	2008 - 2011	774	Risk of Cardiovascular and Renal Events in Type 2 Diabetes
DISCOVER	2015 - ongoing	138	Type 2 Diabetes in Real World Setting
HAT	2012 - 2013	750	Type 2 Diabetes: Hypoglycaemia
ALECARDIO	2009 - 2013	5.760	Acute Coronary Syndrome in Type 2 Diabetes
OBS-FIBER	2014 - 2015	128	Changes in gut transit time and symptoms when using a fibre containing product
MACH15	2017 - ongoing	Ongoing (2500 planned)	Risk of CV death and type 2 diabetes when using moderate quantities of alcohol



Prof. dr. Joost Hoekstra's scientific expertise is focused on clinical diabetology. In this broad area he supported some 20 PhD students and gave numerous lectures. He was co-author of some 225 scientific publications, the majority of which dealt with diabetes. Professor Hoekstra is one of our Associated Scientists.



Broederplein 41-43
3703 CD Zeist
The Netherlands

+31 (0)30 656 99 00
info@juliusclinical.com
www.juliusclinical.com